Given that Ebola virus causes severe hemorrhagic fever in humans with mortality rates as high as 90%, rapid and accurate detection of this virus is essential both for controlling infection and preventing further transmission. Here, a one-step qRT-PCR assay for rapid and quantitative detection of an Ebola Zaire strain using GP, VP24 or VP40 genes as a target is introduced. Routine assay conditions for hydrolysis probe detection were established from the manufacturer's protocol used in the assays. The analytical specificity and sensitivity of each assay was evaluated using in vitro synthesized viral RNA transcripts. The assays were highly specific for the RNA transcripts, no crossreactivity being observed among them. The limits of detection of the assays ranged from 10 2 to 10 3 copies per reaction. The assays were also evaluated using viral RNAs extracted from cell culturepropagated viruses (Ebola Zaire, Sudan and Reston strains), confirming that they are gene-and strainspecific. The RT-PCR assays detected viral RNAs in blood samples from virus-infected animal, suggesting that they can be also a useful method for identifying Ebola virus in clinical samples.
Ebola viruses cause severe hemorrhagic fever with high mortality rates in humans and non-human primates. A recent Ebola virus epidemic in West Africa with more than 28,000 cases and over 11,000 deaths was the largest outbreak of Ebola virus disease (EVD) ever recorded (1) . The virus that caused that outbreak has been characterized as the Makona variant of the Zaire ebolavirus species (2) . The genus Ebolavirus, within the family Filoviridae, includes the following five species: Zaire ebolavirus (EBOV), Sudan ebolavirus (SUDV), Reston ebolavirus (RESTV), Bundibugyo ebolavirus and Tai Forest ebolavirus. Among these, EBOV, SUDV and Bundibugyo ebolavirus cause severe hemorrhagic fever in humans, EBOV having the highest average fatality rate at 78% (3, 4) .
Clinically, EVD patients have non-specific flu-like symptoms to hemorrhagic complications and multiple organ failure, which usually appear in the late stage of the disease. The incubation period of EVD in human varies, symptoms characteristically beginning from 3 to 13 days after exposure (5) . This lengthy silent period can create difficulties in halting transmission and identifying the disease. Avoidance of rapid dissemination of the disease to the community requires rapid and accurate identification of the causative agent from a suspected case. Antigencapture ELISA of clinical specimens (serum and oral fluid) combined with a sensitive nested RT-PCR assay is very effective for detecting Ebola viruses in patients (6) . However, these assays have limited throughput capacity and it takes need up to a day to acquire the results (7) . To overcome these limits, many groups have developed real-time RT-PCR assays that have both high sensitivity and high throughput capacity (8) (9) (10) (11) (12) (13) . Although real-time RT-PCR assays are routinely used to detect Ebola viruses, development and testing of these assays is limited and performed only in restricted areas of specialized laboratories. Moreover, RNA templates as positive controls are not always available and safe for highly infective pathogens such as Ebola viruses. Therefore, reliable methods for obtaining RNAs safely from highly infectious viruses and for establishing easier ways of developing a method for simple and rapid detection of these viruses is desperately needed in general laboratories.
In this study, we introduce hydrolysis probe (TaqMan; Thermo Fisher Scientific, Pittsburgh, PA, USA)-based one-step qRT-PCR assay methods for targeting the GP, VP24 and VP40 genes of EBOV. For rapid testing, all the RT-PCR assays can be performed in a run on a LightCycler instrument (Roche Molecular Diagnostics, Pleasanton, CA, USA) with general cycling conditions according to the manufacturer's protocol for the reagents used. We also demonstrate that the RT-PCR assays against different target genes show very similar efficiency and that each assay can be used separately for quantification of viral RNA in virus-infected animal blood samples.
MATERIALS AND METHODS

Virus and biosafety
Ebola virus stocks (EBOV, SUDV and RESTV) were propagated in Vero E6 cells as described previously (14) . The cells were infected at a MOI of 0.01 per cell. On day seven post-infection, the viruses were harvested and infectious titers determined by virus plaque assay (15) . All work with infectious Ebola viruses were performed within a BSL4 facility at the Texas Biomedical Research Institute (San Antonio, TX, USA), which is certified by the Centers for Disease Control and Prevention.
RNA isolation
The virus-infected cells were inactivated by mixing with TRIzol(LS reagent (Life Technologies, Carlsbad, CA, USA) in clean screw-top micro-centrifuge tubes (16) . Viral RNAs were then extracted from the inactivated samples according to the TRIzol(LS reagent instructions. Total RNAs from animal blood sample were isolated using a RiboPure-Blood kit (Ambion, Austin, TX, USA) according to the manufacturer's instructions. The isolated RNAs were quantified by using a Qubit 1 RNA BR Assay Kit (Life Technologies).
Primers/probe design
The genome sequence of a representative Ebola virus strain, Mayinga (subtype Zaire) was downloaded from the National Center for Biotechnology Information database using GenBank accession number (NC_002549). Based on the genome sequence, sequence alignments to identify conserved regions of the GP and matrix protein (VP24 and VP40) genes from other EBOV strains were done using the BLAST program at the National Center for Biotechnology Information website (17) . Each primers/ probe set was designed with Primer Express Software (version 2.0, Applied Biosystems, Foster, CA, USA). The gene-specific primers/probe set listed in Table 1 were simply selected within standard design constraints (melting temperature 55°-65°C, GC content 40%-60%, no hairpins and the lowest penalty score). All hydrolysis probes were labeled with 6-carboxyfluorescein at the 5 0 end and with 6-carboxytetramethylrhodamine at the 3 0 end. The primers and probes were synthesized by Applied Biosystems.
Optimization of qRT-PCR
qRT-PCR assays were optimized using RNA UltraSense one-step qRT-PCR kit (Thermo Fisher Scientific) according to the manufacturer's protocol as previously described (14) . Briefly, a typical reaction mixture in duplicate contained 2 mL of 5 Â reaction mix, 0.5 mL of enzyme mix, 0.5 mL of 20 Â BSA, 250 nM of each primer, 250 nM of hydrolysis probe and RNA sample in a final volume of 10 mL. qRT-PCR amplification was performed on a LightCycler 2.0 capillary instrument with the corresponding software interface (version 4.05, Roche, Germany) set at the default thermal profile (RT reaction at 45°C for 30 min, platinum Taq polymerase activation at 95°C for 2 min, 45 cycles of denaturation at 95°C for 15 s and annealing/extension at 60°C for 30 s) with a single acquisition of fluorescence.
Preparation of in vitro synthesized RNA transcripts
Viral RNA standards for qRT-PCR were prepared by in vitro RNA transcription. Briefly, each target region was amplified by RT-PCR using a OneStep RT-PCR kit (Qiagen, Gaithersburg, MD, USA) with the primers listed in Table 1 and then cloned directly into pGEM-T-Easy vector (Promega, Madison, WI, USA). The presence and orientation of the inserts were confirmed
Ebola virus detection by qRT-PCR assay
by restriction enzyme digestion analysis. The plasmids with each gene fragment (GP, VP40 and VP24) were linearized by digestion with NdeI and in vitro transcribed using a MEGAscript T7 kit (Ambion). Following TURBO DNase treatment, the synthetic viral RNA transcripts were purified with an RNeasy Mini kit (Qiagen). The purified RNA transcripts were quantified with a Qubit RNA BR assay kit (Invitrogen, Carlsbad, CA, USA), divided into aliquots (10 ng/mL), and stored at À80°C for further use.
Specificity, sensitivity and reproducibility
To assess the specificity of the one-step qRT-PCR assay, each primers/probe set was tested in duplicate against in vitro synthesized different viral RNA transcripts at concentrations of 0.2 ng/tube, viral RNA extracts of EBOV, SUDV and RESTV at concentrations of 2 ng/ tube, and total RNA extracts of blood samples collected previously from EBOV-infected marmosets (18) . To evaluate the sensitivity and LOD, 10-fold serial dilutions of synthetic viral RNA transcripts ranging from 10 À10 to 10 À15 gram/mL were used and a standard curve was created by plotting Cp values against the logarithm of their known initial template copy numbers. The equivalent target copy number for absolute quantification was calculated by an equation based on the molecular weight and length of the target sequence (19) . The efficiency of PCR amplification was determined using the software interface ver. 4.05 equipped in the LightCycler 2.0 instrument. Two replicates of the assay were performed within runs to assess reproducibility and assay variations over the linear range of the assays were statistically calculated.
Statistical analysis
Regression and the CV of the mean Cp values for each standard concentration within and between individual RT-PCR runs were statically calculated by using SigmaPlot 12 (Systat Software) to evaluate linearity and determine the qualitative performance of each assay.
RESULTS
Synthetic viral RNA transcript standards for qRT-PCR assays
The viral RNA standards synthesized by in vitro T7 RNA transcription system were pure enough for qRT-PCR assays because the ratios of absorbance at 260 and 280 nm (A 260 /A 280 ) of all the purified RNA transcripts were between 2.0 and 2.1. The concentrations of the RNA transcripts ranged from 246ng/mL to 494 ng/mL. Copy numbers were calculated according to the concentration and size of each single-stranded RNA fragment (Table 2) .
Sensitivity, reproducibility and specificity of the assays One-step qRT-PCR assays on different gene targets (GP, VP24 and VP40) yielded specific sigmoid amplification curves with reproducible results without any background signals (Fig. 1) . The sensitivity of each assay was evaluated by using serial dilutions (10 À10 to 10À 15 g/mL) of in vitro synthesized viral RNA transcripts. Cp values were calculated from amplification plots covering the range of dilutions and used to draw standard curves. The linearity of each standard curve allowed quantification of viral RNA molecules in a wide range from 10 3 to 10 9 per reaction (Fig. 2) . As shown in Table 3 , their efficiency rates were as high as between 1.914 AE 0.006 and 1.960 AE 0.031, which are within the significant range. Also, all the curves had very similar slope values (À3.394 to À3.561) and coefficients of determination (r 2 ) (0.9980 to 0.9999). The potential LODs of the assays were determined to be from 10 2 (VP24 and VP40) to 10 3 (GP) RNA copies at a cut-off Cp ( 35). The intra-assay CVs of Cp values were within the acceptable limit of <5%. To evaluate the specificity of the assays, crossreactivity was examined using in vitro synthesized viral RNA transcripts at a concentration of 0.2 ng per reaction as templates. Each primers/probe set for three target genes (GP, VP24 and VP40) of EBOV showed high positive fluorescence signals in the Cp ranges of 9.05 to 14.51 to only the RNA transcript synthesized from its own template; no cross-amplification reactions were observed among them (data not shown). When 2 ng of viral RNA extracts from EBOV-, SUDV-and RESTV-infected cells were used as templates, three primers/probe sets for EBOV genes (GP, VP24 and VP40) reacted only to EBOV RNA extract (Table 4) . None of them showed any fluorescence signals with SUDV and RESTV RNA extracts.
Suitability for diagnostics and quantification of virus in clinical specimens
To test the suitability of the assays with clinical specimens, total RNAs were isolated from frozen blood samples of EBOV-infected marmosets, which become ill at 2 DPI and die of disease at 4 DPI (18), and used in the one-step qRT-PCR assays developed here. When total RNA extracts at different DPI were amplified in parallel with each synthesized RNA transcripts (GP, VP24 and VP40) as quantification standards, blood samples collected before EBOV infection (0 DPI) showed no sign of amplification with each primers/probe set. However, viral RNAs were specifically detected in the blood samples at 2 and 4 DPI with each primers/probe set, average viral genome concentrations being 3.84 Â 10 7 and 1.24 Â 10 10 genome equivalents/mL of blood (Table 5) , respectively, indicating a clear correlation between viral load and duration of illness. Taken together, these results suggest that the assay methods shown here are also suitable for clinical specimens.
DISCUSSION
Because of its high mortality rate up to 90%, reliable methods of completely inactivating Ebola virus must be established prior to routine processing and diagnosing of viruses by RT-PCR in general laboratories. Here, we mainly used TRIzol LS reagent for isolation of total RNA from virus-infected cells because it completely inactivates high titers of filoviruses, including ebolavirus (16) , and it is also a common, ready-to-use reagent designed to isolate high-quality total RNA from liquid biological samples including viruses. For total RNA isolation from animal blood samples, we used a RiboPure-Blood kit (Ambion) because these kits specifically isolate high quality total RNA from anticoagulated whole blood and isolation procedures are based on cell-lysis of guanidinium-based solution and phenol-chloroform extraction, identical to those of TRIzol LS reagent. Moreover, these kits have already been confirmed to completely inactivate ebolaviruses when used to isolate total RNA from EBOV-infected animal blood samples (14) . The inactivation methods described here are suitable for use in general and field laboratories that are not standard BSL4 laboratories. After inactivation, samples can be manipulated outside containment, thus increasing sample throughput with no need for additional operative protection other than good laboratory practice.
Ebola virus RNA genome encodes seven viral proteins in the following order nucleoprotein, phosphoprotein (VP35), matrix protein (VP40), GP, replicationtranscription protein (VP30), matrix protein (VP24), Table 3 were plotted against the log of the initial starting quantity of each RNA standard (copies/run). and polymerase (L), with an additional soluble GP produced from an edited GP mRNA (20, 21) . Molecular assays based on RT-PCR have been successfully applied in the diagnosis of Ebola virus genome, their targets for detection being exclusively on the L, nucleoprotein or GP gene (8, (10) (11) (12) (13) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . In this study, we selected the primers/probe set for EBOV GP, VP24 and VP40 gene detection and tested them in one-step qRT-PCR assays.
The assays with the selected primers/probe set for VP24 and VP40 gene detection showed reliable standard curves and strong linear correlations with high amplification efficiencies similar to those for GP gene detection (14) . Most importantly, no significant nonspecific amplification was observed with in vitro transcribed viral RNAs and total RNA extracts of three viral isolates (EBOV, SUDV and RESTV). The reproducibility of the assays was also acceptable because the CVs of Cp values were all less than 5% in each dilution of synthesized viral RNAs, suggesting that any gene of Ebola virus can be used in RT-PCR as a target and all the primers/probe set in this study are highly specific for their targets. The reliability of qRT-PCR assays principally depends on the quality of RNA standards. We used in vitro synthesized RNA transcripts as RNA standards for qRT-PCR and their purity was acceptable because the ratios of A 260 /A 280 were between 2.0 and 2.1. Moreover, standard curves generated by using different RNA transcripts revealed strong linear correlations with high amplification efficiencies in our qRT-PCR assays and all assays were reproducible and reliable. The linear range of Ebola viral RNA quantitation in this study was 10 3 to 10 9 copies per reaction and LODs of the assays ranged from 10 2 copies (VP24 and VP40 RNA targets) to 10 3 copies (GP RNA target) at a cut-off Cp of 35; these sensitivities are similar to those of other published previously filovirus detection assays (8, 11, 13, 29) . In addition to the quality of RNA standards, choosing the right instruments and reaction mixtures is also important when developing appropriate qRT-PCR assays. Although we designed our assays using a Roche LightCycler 2.0, all assays would be transferable with minimal master mixture adjustments to most TaqMan-compatible machines because a previous study has demonstrated easy transfer of both probe chemistries from one platform to another through similar performance, sensitivity, and specificity on three different instruments, namely the R.A.P.I.D (Idaho Technology, Salt Lake City, UT, USA), LightCycler (Roche), and Smart Cycler (Cepheid, Sunnyvale, CA, USA) platforms (32) . We optimized the qRT-PCR assay using a RNA UltraSense one-step qRT-PCR kit (Thermo Fisher Scientific, USA) with a universal reaction condition recommended by the manufacturer. However, other commercially available reagents such as AgPath-ID one-step RT-PCR kits (Thermo Fisher Scientific) and iScript one-step RT-PCR kits (Bio-Rad, Hercules, CA, USA) also yield comparable results with high efficiency, similar to that of RNA UltraSense one-step qRT-PCR kit (unpublished results), suggesting that the reagents used in other qRT-PCR assays are likely compatible with those used in our protocol.
Comparing the sensitivity and detection time of our qRT-PCR assay to those of other assays (9-13) previously reported for detecting EBOV genome reveals that our protocol has some advantages, including rapid detection time (less than 70 min), and moderate and compatible ranges of sensitivity (more detailed descriptions are provided in Table 6 ). Moreover, in this study we scaled down the total reaction volume from the manufacturer-recommended 25 or 20 mL to 10 mL per reaction with little change in RT-PCR efficiency. This reaction volume reduction makes qRT-PCR assays less costly because the reaction mixture contains expensive components such as probe and reagent mix.
In conclusion, the assays developed in this study are highly specific and sensitive for the detection of GP, VP24 and VP40 genes of EBOV. Complete inactivation of infectious Ebola virus with general RNA extraction reagent, simple design of primers/probe set, a simple optimization assay protocol recommended by the manufacturer, and common rapid-cycling parameters mean that precise detection of Ebola virus is possible even in general laboratories. The assay costs less per sample than other assays because we use minimum amounts of all reagents and can provide accurate results in a short time frame (less than an hour). Most importantly, because these are absolute qRT-PCR assays, researchers will be able to detect and identify EBOV from unknown samples, and use the assays for viral load, vaccine, and antiviral drug studies. These characteristics make it potentially useful for the clinical diagnosis and management of EBOV outbreaks in areas where it is epidemic. 
